RBM39 and breast carcinoma: These findings align with previous research showing that inhibiting RBM39 with peptides that strongly bind to c-Jun and block full-length RBM39 access increased DNA damage marker γ-H2AX levels and promoted apoptosis in breast cancer cells 36.